Although the accuracy of our model is still somewhat insufficient to apply to all ER+HER2− breast cancer patients, it is expected to be feasible in a well-selected group with variables such as PR positivity, Ki-67 levels < 20, and premenopausal status. The gene discussed is MKI67; the disease is breast carcinoma.